Cytokinetics Inc CYTK
We take great care to ensure that the data presented and summarized in this overview for CYTOKINETICS INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding CYTK
View all-
T. Rowe Price Investment Management, Inc. Baltimore, MD17.6MShares$1.06 Billion0.37% of portfolio
-
Black Rock Inc. New York, NY14.7MShares$883 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.9MShares$713 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA7.83MShares$471 Million0.05% of portfolio
-
State Street Corp Boston, MA6.37MShares$383 Million0.01% of portfolio
-
Deep Track Capital, LP Greenwich, CT3.65MShares$220 Million4.28% of portfolio
-
Ubs Group Ag3.07MShares$185 Million0.02% of portfolio
-
Geode Capital Management, LLC Boston, MA2.99MShares$180 Million0.01% of portfolio
-
Vestal Point Capital, LP New York, NY2.98MShares$179 Million5.18% of portfolio
-
Polar Capital Holdings PLC London, X02.8MShares$168 Million0.53% of portfolio
Latest Institutional Activity in CYTK
Top Purchases
Top Sells
About CYTK
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy; and CK-3772271, a small molecule cardiac myosin inhibitor that is in Phase I clinical trial. Cytokinetics, Incorporated has a strategic alliance with Astellas Pharma Inc. The company was incorporated in 1997 and is headquartered in South San Francisco, California.
Insider Transactions at CYTK
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 05
2025
|
Robert I Blum President & CEO |
SELL
Bona fide gift
|
Direct |
2,000
-0.56%
|
-
|
|
Nov 04
2025
|
Fady Ibraham Malik EVP Research & Development |
SELL
Open market or private sale
|
Direct |
2,295
-1.61%
|
$135,405
$59.55 P/Share
|
|
Nov 04
2025
|
Fady Ibraham Malik EVP Research & Development |
BUY
Exercise of conversion of derivative security
|
Direct |
2,295
+1.58%
|
$22,950
$10.6 P/Share
|
|
Oct 30
2025
|
Robert I Blum President & CEO |
SELL
Open market or private sale
|
Direct |
5,000
-1.38%
|
$310,000
$62.86 P/Share
|
|
Oct 27
2025
|
Wendell Wierenga Director |
SELL
Open market or private sale
|
Direct |
4,375
-11.88%
|
$253,750
$58.68 P/Share
|
|
Oct 27
2025
|
Wendell Wierenga Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,375
+10.62%
|
$43,750
$10.0 P/Share
|
|
Oct 21
2025
|
Fady Ibraham Malik EVP Research & Development |
SELL
Open market or private sale
|
Direct |
2,105
-1.48%
|
$122,090
$58.22 P/Share
|
|
Oct 21
2025
|
Fady Ibraham Malik EVP Research & Development |
BUY
Exercise of conversion of derivative security
|
Direct |
2,105
+1.45%
|
$21,050
$10.6 P/Share
|
|
Oct 16
2025
|
Robert I Blum President & CEO |
SELL
Open market or private sale
|
Direct |
5,000
-1.36%
|
$300,000
$60.03 P/Share
|
|
Oct 15
2025
|
Wendell Wierenga Director |
BUY
Grant, award, or other acquisition
|
Direct |
99
+0.3%
|
$6,138
$62.8 P/Share
|
|
Oct 15
2025
|
Edward M. Md Kaye Director |
BUY
Grant, award, or other acquisition
|
Direct |
199
+1.96%
|
$12,338
$62.8 P/Share
|
|
Oct 15
2025
|
John T Henderson Director |
BUY
Grant, award, or other acquisition
|
Direct |
338
+0.45%
|
$20,956
$62.8 P/Share
|
|
Oct 15
2025
|
Robert Arthur Harrington Director |
BUY
Grant, award, or other acquisition
|
Direct |
199
+0.95%
|
$12,338
$62.8 P/Share
|
|
Oct 15
2025
|
Nancy Wysenski Director |
BUY
Grant, award, or other acquisition
|
Direct |
99
+0.32%
|
$6,138
$62.8 P/Share
|
|
Oct 07
2025
|
Fady Ibraham Malik EVP Research & Development |
SELL
Open market or private sale
|
Direct |
2,000
-1.4%
|
$120,000
$60.56 P/Share
|
|
Oct 07
2025
|
Fady Ibraham Malik EVP Research & Development |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+1.38%
|
$20,000
$10.6 P/Share
|
|
Oct 06
2025
|
Edward M. Md Kaye Director |
SELL
Open market or private sale
|
Direct |
6,757
-40.86%
|
$405,420
$60.0 P/Share
|
|
Oct 01
2025
|
Robert I Blum President & CEO |
SELL
Open market or private sale
|
Direct |
5,000
-1.34%
|
$275,000
$55.05 P/Share
|
|
Sep 30
2025
|
Edward M. Md Kaye Director |
SELL
Open market or private sale
|
Direct |
6,695
-28.82%
|
$368,225
$55.08 P/Share
|
|
Sep 23
2025
|
Fady Ibraham Malik EVP Research & Development |
SELL
Open market or private sale
|
Direct |
2,000
-1.4%
|
$98,000
$49.28 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 332K shares |
|---|---|
| Exercise of conversion of derivative security | 147K shares |
| Open market or private sale | 392K shares |
|---|---|
| Payment of exercise price or tax liability | 16K shares |
| Bona fide gift | 2.2K shares |